Global /South Korea /Healthcare /Medical Devices /205470
chevron_leftBack
Humasis Co. Ltd. logo

Humasis Co. Ltd.

205470
KRX: 205470 Delayed
4,005KRW -1.7%
2.62 USD
As of 13 June 2026, Humasis Co. Ltd. has a market cap of $14.73M USD, ranking #39094 globally and #2476 in South Korea. It ranks #3488 in the Healthcare sector, and #741 in the Medical Devices industry.
Global Rank
39094
Country Rank
2476
Sector Rank
3488
Industry Rank
741
Key Stats
Market Cap
$14.73MUSD
22.4B KRW
Enterprise Value
-$53.89MUSD
-82.24B KRW
Revenue (TTM)
$19.8MUSD
30.11B KRW
EBITDA (TTM)
-$5.72MUSD
-8.73B KRW
Net Income (TTM)
-$10.27MUSD
-15.62B KRW
EBITDA Margin
-29%
Profit Margin
-52%
PS Ratio
3.0
PB Ratio
0.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Sung-gon Kim open_in_new
Employees
69
Founded
2000
Website
humasis.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.7% 5.7% 9.1% -18% -39% -41%

News

Loading...

Markets

Exchange Ticker Price
Korea Exchange
MIC: XKRX
PRIMARY
205470
휴마시스(주)
ISIN: KR7205470008
Shares Out.:
21.431M1 Shares Float: 4.788M2
TV:
SA:
YF:
GF:
BA:
MS:
4,005 KRW
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Humasis Co. Ltd.

Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women’s health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface proteins, COVID-19 RT-PCR kit, and COVID-19 Variant RT-qPCR kit, as well as MPXV real time PCR kit, a real-time polymerase chain reaction assay for the qualitative detection of nucleic acid from Monkeypox virus. In addition, it offers diagnostic equipment, such as urinalysis, blood glucose meters, and immunodiagnostics tools. Further, it provides other test kits, such as Cotinine to test cotinine in urine; and G6PD, an in vitro diagnostic test that can detect glucose-6-phosphate dehydrogenase in human whole blood. The company was founded in 2000 and is headquartered in Anyang-si, South Korea.

Similar Companies

Industry: Medical Devices (South Korea)
Name
Market Cap diff.
PE
214150
$2.47B
3.75T KRW
17K%
28.7
458870
$1.23B
1.86T KRW
8K%
114.8
491000
$1.19B
1.81T KRW
8K%
-
290650
$1.14B
1.74T KRW
8K%
-
096530
$759.58M
1.16T KRW
5K%
23.9
214430
$532.37M
809.64B KRW
4K%
83.3
Industry: Medical Devices (Global)
Name
Market Cap diff.
PE
$173.27B
1M%
25.8
$160.73B
1M%
56.7
$159.07B
1M%
25.6
DHR
$126.55B
859K%
34.7
SYK
$120.69B
819K%
38.3
MDT
$101.9B
692K%
22.2
chevron_leftBack